|
| 37211198 | Cardiopulmonary testing in long COVID-19 versus non-COVID-19 patients with undifferentiated Dyspnea on exertion. | Prog Cardiovasc Dis | 2024 |
| 36894741 | COVID-19, the Gut, and Nutritional Implications. | Curr Nutr Rep | 2023 |
| 37859995 | Rates Among Hospitalized Patients With COVID-19 Treated With Convalescent Plasma: A Systematic Review and Meta-Analysis. | Mayo Clin Proc Innov Qual Outcomes | 2023 |
| 37485961 | Risk factors for post-acute sequelae of COVID-19: Survey results from a tertiary care hospital. | J Investig Med | 2023 |
| 37793728 | Diagnosis and Management of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome. | Mayo Clin Proc | 2023 |
| 37516512 | Functional Gastrointestinal Disorders. | Prim Care | 2023 |
| 35787711 | Stress Resilience Program for Health Care Professionals During a Pandemic: A Pilot Program. | Workplace Health Saf | 2023 |
| 37419575 | Post-COVID Conditions. | Mayo Clin Proc | 2023 |
| 37140483 | Perioperative cardiac risk reduction in non cardiac surgery. | Minerva Med | 2023 |
| 37368875 | Inflammatory Arthritis After COVID-19: A Case Series. | Am J Case Rep | 2023 |
| 36960553 | Mindfulness Using a Wearable Brain Sensing Device for Health Care Professionals During a Pandemic: A Pilot Program. | J Prim Care Community Health | 2023 |
| 36644593 | Association of Neutralizing Antispike Monoclonal Antibody Treatment With Coronavirus Disease 2019 Hospitalization and Assessment of the Monoclonal Antibody Screening Score. | Mayo Clin Proc Innov Qual Outcomes | 2023 |
| 36872195 | Estradiol and Dihydrotestosterone Levels in COVID-19 Patients. | Mayo Clin Proc | 2023 |
| 34379766 | Reply to Puing et al. | J Infect Dis | 2022 |
| 35352605 | Virtual Reality for Health Care Professionals During a Pandemic: A Pilot Program. | J Prim Care Community Health | 2022 |
| 35769314 | Patient Perspectives on Anti-spike Monoclonal Antibody Therapy for Mild to Moderate Coronavirus Disease-2019. | J Patient Exp | 2022 |
| 35669936 | Postacute Sequelae of SARS-CoV-2 Infection-Lessons Learned From a Coordinated Health System Response. | Mayo Clin Proc Innov Qual Outcomes | 2022 |
| 35642461 | Dietary Supplements for Pain Relief in Patients with Fibromyalgia: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. | Am J Chin Med | 2022 |
| 35791358 | Outcomes of B-Cell-Depleted Patients With Coronavirus Disease 2019 Treated With Antispike Monoclonal Antibodies. | Open Forum Infect Dis | 2022 |
| 35396239 | Post-COVID-19 syndrome: persistent neuroimaging changes and symptoms 9 months after initial infection. | BMJ Case Rep | 2022 |
| 35787866 | Preoperative Evaluation and Management of Patients With Select Chronic Gastrointestinal, Liver, and Renal Diseases. | Mayo Clin Proc | 2022 |
| 35512884 | Rates of Severe Outcomes After Bamlanivimab-Etesevimab and Casirivimab-Imdevimab Treatment of High-Risk Patients With Mild to Moderate Coronavirus Disease 2019. | Mayo Clin Proc | 2022 |
| 35848574 | Outcomes of bebtelovimab and sotrovimab treatment of solid organ transplant recipients with mild-to-moderate coronavirus disease 2019 during the Omicron epoch. | Transpl Infect Dis | 2022 |
| 36544937 | Patient factors associated with COVID-19 loss of taste or smell patient factors in smell/taste loss COVID-19. | Laryngoscope Investig Otolaryngol | 2022 |
| 36464463 | Impact of a High-Risk, Ambulatory COVID-19 Remote Patient Monitoring Program on Utilization, Cost, and Mortality. | Mayo Clin Proc | 2022 |
| 36213724 | Real-world Clinical Outcomes of Bebtelovimab and Sotrovimab Treatment of High-risk Persons With Coronavirus Disease 2019 During the Omicron Epoch. | Open Forum Infect Dis | 2022 |
| 35969000 | Outcomes of Solid Organ Transplant Recipients Treated With Antispike Monoclonal Antibodies for Coronavirus Disease 2019 Across Variant Epochs: Impact of Comorbidities and Vaccination. | Transplantation | 2022 |
| 36058578 | Curbing the Delta Surge: Clinical Outcomes After Treatment With Bamlanivimab-Etesevimab, Casirivimab-Imdevimab, or Sotrovimab for Mild to Moderate Coronavirus Disease 2019. | Mayo Clin Proc | 2022 |
| 36124696 | Comparable Outcomes for Bebtelovimab and Ritonavir-Boosted Nirmatrelvir Treatment in High-Risk Patients With Coronavirus Disease-2019 During Severe Acute Respiratory Syndrome Coronavirus 2 BA.2 Omicron Epoch. | J Infect Dis | 2022 |
| 36156121 | Vaccine-boosted convalescent plasma therapy for patients with immunosuppression and COVID-19. | Blood Adv | 2022 |
| 35120695 | Effectiveness of Monoclonal Antibodies in Preventing Severe COVID-19 With Emergence of the Delta Variant. | Mayo Clin Proc | 2022 |
| 34996562 | Clinical Prioritization of Antispike Monoclonal Antibody Treatment of Mild to Moderate COVID-19. | Mayo Clin Proc | 2022 |
| 35026789 | Anti-Spike Monoclonal Antibody Therapy in Pregnant Women With Mild-to-Moderate Coronavirus Disease 2019 (COVID-19). | Obstet Gynecol | 2022 |
| 34932874 | Breakthrough COVID-19 after SARS-CoV-2 vaccination in solid organ transplant recipients: An analysis of symptomatic cases and monoclonal antibody therapy. | Transpl Infect Dis | 2022 |
| 35135695 | The Female-Predominant Persistent Immune Dysregulation of the Post-COVID Syndrome. | Mayo Clin Proc | 2022 |
| 34791298 | Monoclonal Antibody Treatment of Breakthrough COVID-19 in Fully Vaccinated Individuals with High-Risk Comorbidities. | J Infect Dis | 2022 |
| 33375924 | Battlefield Acupuncture for Adult Pain: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. | Am J Chin Med | 2021 |
| 33521583 | Managing Patients in the COVID-19 Pandemic: A Virtual Multidisciplinary Approach. | Mayo Clin Proc Innov Qual Outcomes | 2021 |
| 33741131 | Preoperative Management of Surgical Patients Using Dietary Supplements: Society for Perioperative Assessment and Quality Improvement (SPAQI) Consensus Statement. | Mayo Clin Proc | 2021 |
| 33619724 | A mobile unit overcomes the challenges to monoclonal antibody infusion for COVID-19 in skilled care facilities. | J Am Geriatr Soc | 2021 |
| 33673913 | Outcomes of COVID-19 With the Mayo Clinic Model of Care and Research. | Mayo Clin Proc | 2021 |
| 34411003 | Intravenous bamlanivimab use associates with reduced hospitalization in high-risk patients with mild to moderate COVID-19. | J Clin Invest | 2021 |
| 34631921 | Monoclonal Antibody Therapy for COVID-19 in Solid Organ Transplant Recipients. | Open Forum Infect Dis | 2021 |
| 34485873 | Casirivimab-Imdevimab treatment is associated with reduced rates of hospitalization among high-risk patients with mild to moderate coronavirus disease-19. | EClinicalMedicine | 2021 |
| 34775142 | Breakthrough COVID-19 and casirivimab-imdevimab treatment during a SARS-CoV-2 B1.617.2 (Delta) surge. | J Clin Virol | 2021 |
| 34389787 | Implementation of a multisite, interdisciplinary remote patient monitoring program for ambulatory management of patients with COVID-19. | NPJ Digit Med | 2021 |
| 34075387 | Association of Intravenous Bamlanivimab Use with Reduced Hospitalization, Intensive Care Unit Admission, and Mortality in Patients with Mild to Moderate COVID-19. | medRxiv | 2021 |
| 33958056 | A Framework for Outpatient Infusion of Antispike Monoclonal Antibodies to High-Risk Patients with Mild-to-Moderate Coronavirus Disease-19: The Mayo Clinic Model. | Mayo Clin Proc | 2021 |
| 34032171 | Influence of Social and Cultural Factors on the Decision to Consent for Monoclonal Antibody Treatment among High-Risk Patients with Mild-Moderate COVID-19. | J Prim Care Community Health | 2021 |
| 34231404 | Central Sensitization Phenotypes in Post Acute Sequelae of SARS-CoV-2 Infection (PASC): Defining the Post COVID Syndrome. | J Prim Care Community Health | 2021 |